⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

May 30, 2024Neurology - the American medical journal.Open Access

Ozanimod Long-Term Safety and Efficacy

European Medical Journal EMJ

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Only 1 serious opportunistic infection has occurred in DAYBREAK(a previously reported case of PML)

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

European Medical Journal EMJ (2024) studied this question.

synapsesocial.com/papers/68e67a9ab6db64358760494e https://doi.org/10.33590/neurolamj/iyaw3561

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in <scp>DAYBREAK</scp> Trial ParticipantsHuman Clinical Trial · 2026
2Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014)2024 · 1 citations
3Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosisHuman Clinical Trial · 2026 · 5 citations
4Updated Study Data for Ozanimod in Relapsing Multiple Sclerosis2024
5Real-world Experience With Ozanimod at Two Academic Multiple Sclerosis Centers With Expanded 24-month Data (P4-20.003)Original Research · 2026
6Safety Patterns over Time with Ozanimod During an Open-label Extension Trial in Patients with Relapsing Multiple Sclerosis (P10-6.012)2024 · 1 citations
7Absolute Lymphocyte Count Around Infections During Phase 3 and Open-label Extension Trials of Ozanimod in Participants with Relapsing Multiple Sclerosis (P10-6.013)2024
8Trial in progress: Phase I trial to evaluate safety of oral azacytidine in combination with pomalidomide as maintenance therapy in AML2025
9Novel Therapies and Targets for Parkinson’s DiseaseNeurology - the American medical journal. · 2025
10Seizure Disorders: Clinical Insights and Review of the Major Clinical Topics Impacting the Reproductive LifespanNeurology - the American medical journal. · 2025

NMore from Neurology - the American medical journal.